Neurocrine Biosciences (NBIX) Misses Q1 EPS by 16c
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $156.23 +0.38%
EPS Growth %: -12.4%
Financial Fact:
Total revenues: 0
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -12.4%
Financial Fact:
Total revenues: 0
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q1 EPS of ($0.90), $0.16 worse than the analyst estimate of ($0.74). Non revenues reported.
"The Company did not report any revenue for the first quarter of 2017 compared to $15.0 million of revenue for the first quarter of 2016, which represented a milestone payment from AbbVie related to the commencement of Phase III studies of elagolix in uterine fibroids.."
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- United Natural Foods (UNFI) Tops Q4 EPS by 8c ; Offers Guidance
- Morgan Stanley upgrades Synopsys as it turns selective on chip stocks
- HSBC lifts S&P 500 year-end target
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
